Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.
Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.
Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.
Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.
Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.
For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.
Exelixis, Inc. (Nasdaq: EXEL) has announced a collaboration with Bristol-Myers Squibb Company for the STELLAR-002 clinical trial, evaluating the combination of XL092 with immuno-oncology therapies for advanced solid tumors. This phase 1b trial will assess the safety and efficacy of XL092, a next-generation tyrosine kinase inhibitor, alongside nivolumab, ipilimumab, and bempegaldesleukin in patients with genitourinary cancers. The trial aims to explore treatment options for those with limited options following disease progression.
Exelixis and Ipsen announced detailed results from the phase 3 COSMIC-311 trial of cabozantinib (CABOMETYX®) in treating radioactive iodine-refractory differentiated thyroid cancer. The trial met its co-primary endpoint, showing a 78% reduction in disease progression risk compared to placebo. Median progression-free survival (PFS) was not reached for cabozantinib, while it was 1.9 months for placebo. The FDA has received a supplemental New Drug Application for cabozantinib, aiming to address urgent treatment needs in this patient population.
Exelixis, Inc. (NASDAQ: EXEL) reported encouraging Phase 2 trial results for CABOMETYX® (cabozantinib) combined with OPDIVO® (nivolumab) in treating advanced non-clear cell renal cell carcinoma (nccRCC). The regimen showed a 47.5% objective response rate (ORR) in patients with papillary histology. The trial involved 47 patients with median follow-up of 13.1 months. Adverse events were noted in 17% of CABOMETYX and 13% of OPDIVO patients, with hypertension and diarrhea being the most common severe reactions. This data will be presented at the 2021 ASCO Annual Meeting.
Exelixis announced positive results from a post-hoc exploratory analysis of the phase 3 CheckMate -9ER trial, showing that CABOMETYX (cabozantinib) combined with OPDIVO (nivolumab) is effective across various patient subgroups with advanced renal cell carcinoma (RCC). This analysis highlights improved efficacy metrics, with median progression-free survival (PFS) of 17.0 months for the combination therapy compared to 8.3 months for sunitinib. The data will be presented at the ASCO 2021 Annual Meeting. The results support CABOMETYX and OPDIVO as viable first-line treatment options.
Exelixis, Inc. (NASDAQ: EXEL) announced positive results from a post-hoc analysis of the phase 3 CheckMate -9ER trial, showing that CABOMETYX® (cabozantinib) combined with OPDIVO® (nivolumab) significantly improves quality-adjusted survival for untreated advanced renal cell carcinoma (RCC) patients compared to sunitinib. The analysis revealed a Q-TWiST gain of 4.0 months, translating to a 16.9% relative gain. Key findings include improved time without symptoms and better overall quality of life, addressing the need for advanced kidney cancer treatments that enhance both efficacy and quality of life.
Exelixis, Inc. (Nasdaq: EXEL) will participate in several virtual investor conferences in June 2021. Key presentations include:
- William Blair 41st Annual Growth Stock Conference on June 2 at 5:00pm EDT.
- Goldman Sachs 42nd Annual Global Healthcare Conference on June 9 at 1:20pm EDT.
- BofA Securities 2021 Napa Biopharma Virtual Conference on June 16 at 1:30pm EDT.
Webcast links are available on www.exelixis.com. Exelixis focuses on developing cancer therapies and has several marketed products, including CABOMETYX®.
Exelixis (NASDAQ: EXEL) announced results from cohort 6 of the COSMIC-021 trial, focusing on cabozantinib combined with atezolizumab for metastatic castration-resistant prostate cancer (CRPC). The trial included 132 patients, with a primary endpoint of objective response rate (ORR). High-risk patients showed an ORR of 27%, with a disease control rate of 88%. No new safety signals were observed, and treatment discontinuation due to adverse events was 12%. Exelixis plans to discuss FDA regulatory submission next, following the encouraging results.
Exelixis reported first-quarter 2021 financial results with total revenues of $270.2 million, up from $226.9 million year-over-year. Net product revenues reached $227.2 million, fueled by the FDA approval of CABOMETYX in combination with OPDIVO for advanced renal cell carcinoma. Despite revenue growth, GAAP net income dropped to $1.6 million from $48.6 million, reflecting increased R&D and administrative expenses. Exelixis maintains its 2021 revenue guidance of $1.15 to $1.25 billion.
Exelixis, Inc. (Nasdaq: EXEL) has entered into an agreement to acquire GamaMabs Pharma's AMHR2 antibody technology, paying $5 million upfront and additional milestone payments upon closing. This acquisition allows Exelixis to take control of GamaMabs' murlentamab, which demonstrated initial safety in clinical trials despite a halt in its development due to modest efficacy. Exelixis plans to apply its ADC capabilities to the AMHR2 technology aiming to expedite the development of novel cancer therapies, enhancing its biotherapeutics portfolio and addressing unmet patient needs.
Exelixis, Inc. (Nasdaq: EXEL) announced that CEO Michael M. Morrissey, Ph.D. will participate in three virtual investor conferences in May 2021. These include the 7th Annual Truist Securities Life Sciences Summit on May 4 at 3:30pm EDT, the BofA Securities 2021 Health Care Conference on May 11 at 2:00pm EDT, and the RBC Capital Markets 2021 Global Healthcare Conference on May 19 at 3:05pm EDT. Webcasts can be accessed via the company's website, and replays will be available for 14 days.
Exelixis focuses on developing new medicines for challenging cancers, with four commercial products available.
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
What is Exelixis Inc. known for?
What are the main products of Exelixis?
When was Cometriq first approved?
Who are the key partners of Exelixis?
What type of cancer is Cometriq used to treat?
What is Cabometyx used for?
Where can I find job opportunities at Exelixis?
How has the financial performance of Exelixis been?
What kind of research does Exelixis focus on?
What is the ticker symbol for Exelixis Inc.?
